01 - Vision
Diagnostics.
Anywhere.
Anytime.
The full process, in under fifteen minutes.
02 - Mission / How we do it
We deliver a universal, self-contained microfluidic ELISA platform.
We do not compete with the world's diagnostics companies on antibody science. We give them, and every other holder of a validated antibody, a way to reach every place their current instruments cannot go.
Fig. 01 / Detection at the biomarker level
One card, any target
The same architecture detects antibodies, antigens, or blood proteins.
One development method
A disciplined, repeatable pathway from validated antibody to manufactured card.
One manufacturing relationship
A single scalable production line serving every vertical we enter.
03 - Platform / Why we can handle it
One card. No lab required. Built to scale from day one.
Lab On Card miniaturizes ELISA, the gold-standard method behind most of the world's protein diagnostics, into a disposable, self-contained card. No pumps, no readers, no electricity to operate.
A result in about fifteen minutes, read by eye or quantified with a smartphone.
Lab On Card was founded and is supported by two technology pioneers: GeneSpector, specializing in biomedical research, and IQS Group, specializing in micro- and nanostructuring.
Biomedical Research
Micro & nanostructuring
Manufacturing capability
1 of ~5
Companies worldwide with the nanostructuring skills to mass-manufacture a card like ours.
Industrial track record
30+ yrs
IQS Group (IQ Structures), co-founder and manufacturing partner.
Feasibility target
~1M
Units per month. A dedicated mass-production feasibility study is currently underway.
Our manufacturing capability is a founding asset of the company.
04 - Proofs / Antibody, antigen, protein
Proven across all three fundamental ELISA formats.
Each result below is anchored to a measured number on real samples. This section proves the platform works, independent of any specific application.
Sample to result in fifteen minutes
Antibody detection
Lab-equivalent
Performance comparable to a commercial laboratory ELISA kit
SARS-CoV-2
Measured side by side against the commercial kit on the same sample set.
Antigen detection
<200
pg/mL detection limit, result in about fifteen minutes instead of four hours
HIV-1 p24
The same target now anchors our first commercial portfolio.
Protein detection
Whole blood
Quantitative detection with no sample preparation step
C-reactive protein
Read by eye or quantified with a smartphone camera.
Three formats, three independent proof points, one platform.
05 - Unlimited potential / Every sector
One platform. Every sector that needs an answer.
The card does not change between markets. The antibody does. That is what makes every one of these sectors reachable with the same production line and the same development method.
01
Human Diagnostics
Urgent care, cardiac, inflammatory and infectious-disease markers.
Primary vertical
02
Veterinary
Companion animal, livestock, and wildlife surveillance.
$9.5 to 9.9B
Market size
03
Food & Agriculture
$27 to 28B
Market size
04
Environmental & Water
$4.7 to 6.5B
Market size
05
Biodefense
Strategic vertical
Same card, same manufacturing line, same development method. Only the antibody changes.
06 - First portfolio / Development progress
Our first execution: a portfolio of infectious disease diagnostics.
We are proving full execution here, from assay to manufacturing to regulatory pathway, before scaling the same method into every other sector above.
Target panel
HIV
Malaria
Dengue
CRP
cCRP
Development progress
Assay development
HIV-1 p24 validated as proof point. Remaining panel targets in development.
Validated
Manufacturing feasibility
Mass-production study underway with co-founder IQS Group.
Underway
Regulatory pathway
MDR-compliant software and documentation in development.
Planned
Field and clinical validation
Planned as manufacturing feasibility is confirmed.
Planned
This is our starting execution, not our ceiling.
07 - Team
Built by people who have done this before.
A small operating team with prior experience taking regulated diagnostic products from assay to manufacture, backed by an industrial co-founder.
Co-Founder and Chief Executive Officer
Michal Pohludka, PhD, MBA
Scientist, serial entrepreneur, and diagnostics executive with 15+ years of experience turning biomedical innovation into businesses. Former Bio-Rad Laboratories executive with a decade of leadership experience in Central Europe and international diagnostics markets. Co-founder of GeneSpector and multiple biomedical ventures. PhD in Molecular Pathology, MSc in Biochemistry & Biotechnology, MBA in Business Management. Now leading Lab On Card with the ambition to make laboratory-grade diagnostics accessible anywhere.
Martin Jotov
Co-Founder & COO
Adam Pruska, PhD
Partnering and Project Manager
Josef Hascyn
Project Manager
Tomas Riedel, PhD
Head of Development
08 - Partnership model with Life Science & Diagnostic Companies
We partner with Life Science and Diagnostic companies under a clear business model.
The path from a validated antibody to a manufactured card runs through us, and it costs you nothing to start.
1
You hold a validated antibody
We identify a target through our own market and technical evaluation, and we come to you with it.
2
You license it for third-party sale
No upfront cost. No co-development funding required from you at any point.
3
We build the card, you get first refusal
Once validated, you hold the first right to become our global distribution partner.
This removes the two objections large organizations raise most often when approached by a small platform company: cost, and commitment.
Corporate structure
Lab On Card operates as a platform company with focused vertical divisions, all sharing one card, one manufacturing relationship, and one development
09 - Contact
Let us talk.
Tell us which side of the platform you are interested in and we will come back with the relevant technical or commercial detail.
Direct
Investors and business development leads are welcome to skip the form entirely.